Crystalline Forms SA-1 and N-2 Monoamine Reuptake Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants often have slow onset of action, unwanted side effects, and are ineffective for a significant subset of patients, necessitating the development of novel monoamine reuptake inhibitors that can rapidly and effectively treat neurological and psychological disorders.
Innovation Solution
Development of crystalline forms SA-1 and N-2 of [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinoline derivatives, which can inhibit the reuptake of norepinephrine, dopamine, and serotonin, offering a rapid onset of action and improved efficacy for treating various neurological and psychological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidepressants are used, then treatment coverage is provided for some patients, but onset of action is slow and efficacy is limited for 30-40% of patients
Solution Approach 1:
The patent modifies the chemical structure parameters of monoamine reuptake inhibitors by introducing specific substituted tetrahydroisoquinoline derivatives with triazolo[1,5-a]pyridinyl groups, optimizing the balance between onset speed and therapeutic efficacy across multiple neurotransmitter systems
Solution Approach 2:
The invention creates multi-functional compounds that simultaneously inhibit reuptake of serotonin, norepinephrine, and dopamine through a single agent, providing broad-spectrum efficacy for multiple neurotransmitter systems rather than targeting one system at a time
2Reliability
If monoamine reuptake inhibitors are used to treat CNS disorders, then therapeutic efficacy is achieved, but side effects occur due to interaction with other receptors
Solution Approach 1:
The patent introduces selective substitution patterns on the tetrahydroisoquinoline core structure that confer selective affinity for monoamine transporters while reducing off-target interactions with muscarinic, histaminic, and adrenergic receptors, thereby minimizing side effects
Solution Approach 2:
The substituted tetrahydroisoquinoline structure acts as an intermediary molecule that achieves therapeutic goals by selectively modulating monoamine reuptake while avoiding unwanted interactions with other receptor systems through optimized molecular geometry and electronic properties
3Productivity
If novel monoamine reuptake inhibitors are developed, then rapid onset of action and improved efficacy can be achieved, but development complexity and time increase
Solution Approach 1:
The patent divides the complex drug development process into modular synthetic steps starting from commercially available tetrahydroisoquinoline precursors, allowing systematic optimization of substitution patterns to achieve rapid onset and improved efficacy while managing development complexity
Solution Approach 2:
The invention employs preliminary structure-activity relationship studies and computational modeling to predict optimal substitution patterns before full synthesis and testing, reducing development time and complexity by identifying promising candidates early in the discovery process
Data Source
AI summary
Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.